Showing results (561-570 of 634) with videos related to

Sort By:
Pageof 64
Nutrients|September 9, 2023
Combined Treatment of <i>Mori folium</i> and Mori Cortex Radicis Ameliorate Obesity in Mice via UCP-1 in Brown AdipocytesDo-Sung Kim, Hwa-Young Lee, Hwa-Jin Kim, et al.
Cancer Research and Treatment|December 8, 2023
A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal CancerKeun-Wook Lee, Sae-Won Han, Tae Won Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 StudyAkihito Kawazoe, Rui-Hua Xu, Pilar García-Alfonso, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2010
Postoperative chemoradiotherapy for extrahepatic bile duct cancerJin-hong Park, Eun Kyung Choi, Seung Do Ahn, et al.
The Lancet. Oncology|May 19, 2015
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialJin Li, Shukui Qin, Ruihua Xu, et al.
Journal of Neuro-Oncology|March 16, 2004
Leptomeningeal carcinomatosis in gastric cancerJae-Lyun Lee, Yoon-Koo Kang, Tae-Won Kim, et al.
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
Cell Stem Cell|March 22, 2016
CD82/KAI1 Maintains the Dormancy of Long-Term Hematopoietic Stem Cells through Interaction with DARC-Expressing MacrophagesJin Hur, Jae-Il Choi, Hwan Lee, et al.
The New England Journal of Medicine|May 30, 2025
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i>-Mutated Colorectal CancerElena Elez, Takayuki Yoshino, Lin Shen, et al.
Investigational New Drugs|July 8, 2022
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumorsFilip Janku, Seung-Hoon Beom, Yong Wha Moon, et al.
Pageof 64